11 resultaten
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to anti-pancreatic cancer antibodies and antigen-binding fragments thereof that bind to pancreatic cancer mucin, preferably to a mucin selected from the group consisting of MUC1, MUC5ac and MUC16. More preferably, the
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 2, 2012, is named IMM315US.txt and is 49,649 bytes in size.
BACKGROUND OF THE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 2, 2012, is named IMM315US.txt and is 49,649 bytes in size.
BACKGROUND OF THE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 28, 2014, is named IMM343US1_SL.txt and is 56,360 bytes in size.
BACKGROUND OF THE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 28, 2014, is named IMM343US1_SL.txt and is 56,360 bytes in size.
BACKGROUND OF THE
The present application is a .sctn.371 application of PCT/CA2006/001867 filed 15 Nov. 2006 which in turn claims priority from U.S. application Ser. No. 11/274,906, the contents of each being incorporated herein by reference as though set forth in full.
FIELD OF INVENTION
The present invention
FIELD OF THE INVENTION
The present invention relates to methods of administration for parenteral and oral compositions of certain epothilone analogs that are characterized by enhanced clinical efficacy.
BACKGROUND OF THE INVENTION
Epothilones are macrolide compounds having utility in the
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 10, 2011, is named IMM33US1.txt and is 49,765 bytes in size.
BACKGROUND OF THE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 10, 2011, is named IMM33US1.txt and is 49,765 bytes in size.
BACKGROUND OF THE
The following examples illustrate the present invention, but it is to be understood that they are given for the purpose of illustration and not limitation.
EXAMPLE 1
A medium (100 l) containing 6.0% soluble starch, 4.0% cotton seed meal, 0.2% (NH.sub.4).sub.2 SO.sub.4, 0.1% yeast extract, 0.2%
TECHNICAL FIELD
The present invention relates to highly tumor selective and biocompatible cationic linear polyphosphazene carrier polymers and their anticancer drug conjugates, and a preparation method thereof.
BACKGROUND ART
Most of the anticancer drugs currently in clinical use for chemotherapy